Kyverna Therapeutics Inc (KYTX)

Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis

Majority of patients met the American College of Rheumatology improvement criteria (ACR70) response by Week 36...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Kyverna Therapeutics Names Greg Martini as Chief Financial Officer

EMERYVILLE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage...

Kyverna Therapeutics to Present at Upcoming Investor Conferences

EMERYVILLE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results

Positive pre-BLA meeting with FDA alignment reached on KYSA-8 single-arm trial in stiff person syndrome (SPS);...

Form 8-K - Current report

Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer

EMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage...

Form 8-K - Current report

Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting

Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and...